scholarly journals Long-Term Effect of Recombinant Human Insulin-Like Growth Factor I on Metabolic and Growth Control in a Patient with Leprechaunism

1998 ◽  
Vol 83 (2) ◽  
pp. 542-549 ◽  
Author(s):  
Jun Nakae ◽  
Mikiko Kato ◽  
Mari Murashita ◽  
Nozomi Shinohara ◽  
Toshihiro Tajima ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Term Effect ◽  
Recombinant Human Insulin ◽  
Normal Range ◽  
Factor I ◽  
Long Term Effect ◽  
Igf I ◽  
Igfbp 3 ◽  
Gh Resistance

Leprechaunism is the most severe form of insulin resistance, manifesting with abnormal glucose metabolism and retarded growth. In the present study, we investigated the biological actions of recombinant human insulin-like growth factor I (rhIGF-I) in fibroblasts derived from a patient with leprechaunism. In the same patient, we also investigated the pharmacokinetics of IGF-I and the long-term effect of rhIGF-I treatment on metabolic control and physical growth. The patient’s fibroblasts showed normal binding of IGF-I, normal phosphorylation of the β-subunit of the IGF-I receptor, and normal[ 3H]thymidine incorporation in response to IGF-I. The fibroblast studies suggested that the patient would respond to IGF-I therapy, but certainly did not exclude the possibility of IGF-I resistance in vivo. Administration of recombinant human GH at the dose of 2.0 IU/kg for 3 consecutive days induced a minimal response of serum total IGF-I and IGF-binding protein-3 (IGFBP-3), suggesting partial GH resistance. To increase the serum total IGF-I level, we administered rhIGF-I with combination therapy of intermittent and continuous sc injection. This sustained the serum total IGF-I level, but not the serum IGFBP-3 level, within the normal range. The patient was treated with combination therapy of rhIGF-I by both sc injection and continuous sc infusion for 6 yr and 10 months. Administration of rhIGF-I at total daily dose of 1.6 mg/kg maintained her growth rate and hemoglobin A1c level nearly within the normal range. These findings suggest 1) that this leprechaun patient has an IGF-Ideficient state and partial GH resistance, as reflected by impaired production of IGF-I and IGFBP-3; 2) that rhIGF-I treatment works effectively for preventing postnatal growth retardation and normalizing glucose metabolism in patients with extreme insulin resistance; 3) that this treatment requires relatively higher dose of rhIGF-I; and 4) that treatment appears to be safe and devoid of adverse effects.

scholarly journals Effects of Recombinant Human Insulin-Like Growth Factor I Administration on Spontaneous and Growth Hormone (GH)-Releasing Hormone-Stimulated GH Secretion in Anorexia Nervosa1

2000 ◽  
Vol 85 (8) ◽  
pp. 2805-2809
Author(s):  
Laura Gianotti ◽  
Angela I. Pincelli ◽  
Massimo Scacchi ◽  
Mimma Rolla ◽  
Deanna Bellitti ◽  
...  
Keyword(s):  
Growth Factor ◽  
Normal Weight ◽  
Insulin Like Growth Factor ◽  
Recombinant Human Insulin ◽  
Releasing Hormone ◽  
Gh Secretion ◽  
Factor I ◽  
Igf I ◽  
Growth Factor I ◽  
Igfbp 3

Exaggerated GH and reduced insulin-like growth factor I (IGF-I) levels are common features in anorexia nervosa (AN). A reduction of the negative IGF-I feedback could account, in part, for GH hypersecretion. To ascertain this, we studied the effects of recombinant human (rh)IGF-I on spontaneous and GH-releasing hormone (GHRH)-stimulated GH secretion in nine women with AN [body mass index, 14.1 ± 0.6 kg/m2] and in weight matched controls (normal weight). Mean basal GH concentrations (mGHc) and GHRH (2.0μ g/kg, iv) stimulation were significantly higher in AN. rhIGF-I administration (20 μg/kg, sc) significantly reduced mGHc in AN (P < 0.01), but not normal weight, and inhibited peak GH response to GHRH in both groups; mGHc and peak GH, however, persisted at a significantly higher level in AN. Insulin, glucose, and IGFBP-1 basal levels were similar in both groups. rhIGF-I inhibited insulin in AN, whereas glucose remained unaffected in both groups. IGFBP-1 increased in both groups (P < 0.05), with significantly higher levels in AN. IGFBP-3 was under basal conditions at a lower level in AN (P < 0.05) and remained unaffected by rhIGF-I. This study demonstrates that a low rhIGF-I dose inhibits, but does not normalize, spontaneous and GHRH-stimulated GH secretion in AN, pointing also to the existence of a defective hypothalamic control of GH release. Moreover, the increased IGFBP-1 levels might curtail the negative IGF-I feedback in AN.

The long-term effect of lowering dialysate magnesium on circulating parathyroid hormone in patients on regular haemodialysis therapy

1980 ◽  
Vol 93 (4) ◽  
pp. 455-460 ◽  
Author(s):  
V. Parsons ◽  
S. E. Papapoulos ◽  
M.J. Weston ◽  
S. Tomlinson ◽  
J. L. H. O'Riordan
Keyword(s):  
Parathyroid Hormone ◽  
Term Effect ◽  
Normal Range ◽  
Dialysis Therapy ◽  
Long Term Effect

Abstract. Measurement of parathyroid hormone (PTH) in a group of patients on regular dialysis therapy (RDT) showed little acceleration of the development of raised concentrations until the dialysate concentration of magnesium was halved from 0.5 to 0.25 mmol/l. Patients with sustained concentrations of PTH changed less than those who were within the normal range at the outset.

Long-Term Effect of Octreotide in Acromegaly on Insulin Resistance

1995 ◽  
Vol 27 (05) ◽  
pp. 226-230 ◽  
Author(s):  
M. Breidert ◽  
T. Pinzer ◽  
J. Wildbrett ◽  
S. Bornstein ◽  
M. Hanefeld
Keyword(s):  
Insulin Resistance ◽  
Term Effect ◽  
Long Term Effect

Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes

2007 ◽  
Vol 194 (1) ◽  
pp. 265-271 ◽  
Author(s):  
Helena Tenenbaum ◽  
Solomon Behar ◽  
Valentina Boyko ◽  
Yehuda Adler ◽  
Enrique Z. Fisman ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Beta Cell ◽  
Beta Cell Function ◽  
Cell Function ◽  
Pancreatic Beta Cell ◽  
Term Effect ◽  
Long Term Effect ◽  
Patients With Diabetes ◽  
Pancreatic Beta Cell Function

scholarly journals Short-term effects of replacing milk with cola beverages on insulin-like growth factor-I and insulin–glucose metabolism: a 10 d interventional study in young men

2009 ◽  
Vol 102 (7) ◽  
pp. 1047-1051 ◽  
Author(s):  
Camilla Hoppe ◽  
Mette Kristensen ◽  
Marlene Boiesen ◽  
Jane Kudsk ◽  
Kim Fleischer Michaelsen ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Growth Factor ◽  
Cell Function ◽  
Β Cell ◽  
High Intake ◽  
Insulin Metabolism ◽  
Factor I ◽  
Igf I ◽  
Β Cell Function ◽  
Igfbp 3

In the Western world, a trend towards increased consumption of carbonated soft drinks combined with a decreasing intake of milk is observed. This may affect circulating insulin-like growth factor I (IGF-I) and fasting insulin, as seen in pre-pubertal children. The present study was designed to reflect the trend of replacing milk with carbonated beverages in young men and to study the effects of this replacement on IGF-I, IGF-binding protein 3 (IGFBP-3), IGF-I:IGFBP-3 and glucose–insulin metabolism. A randomised, controlled crossover intervention study, in which eleven men aged 22–29 years were given a low-Ca diet in two 10 d periods with 10 d washout in between. In one period, they drank 2·5 litres of Coca Cola® per day and the other period 2·5 litres of semi-skimmed milk. Serum IGF-I, IGFBP-3 (RIA), insulin (fluoro immunoassay) and glucose (Cobas) were determined at baseline and end point of each intervention period. Insulin resistance and β-cell function were calculated with the homeostasis model assessment. A decrease in serum IGF-I was observed in the cola period compared with the milk period (P < 0·05). No effects of treatment were observed on IGFBP-3, IGF-I:IGFBP-3, insulin, glucose, insulin resistance or β-cell function. The present study demonstrates that high intake of cola over a 10 d period decreases total IGF-I compared with a high intake of milk, with no effect on glucose–insulin metabolism in adult men. It is unknown whether this is a transient phenomenon or whether it has long-term consequences.

Effects of repeated subcutaneous administration of recombinant human insulin-like growth factor I in adults with growth hormone deficiency

1994 ◽  
Vol 131 (1) ◽  
pp. 33-40 ◽  
Author(s):  
Maria C Thorén ◽  
Inga-Lena Wivall-Helleryd ◽  
Werner F Blum ◽  
Kerstin E Hall
Keyword(s):  
Growth Factor ◽  
Subcutaneous Administration ◽  
Metabolic Effects ◽  
Hormone Deficiency ◽  
Insulin Like Growth Factor ◽  
Recombinant Human Insulin ◽  
Factor I ◽  
Igf I ◽  
Growth Factor I ◽  
Igfbp 3

Thorén MC, Wivall-Helleryd I-L. Blum WF, Hall KE. Effects of repeated subcutaneous administration of recombinant human insulin-like growth factor I in adults with growth hormone deficiency. Eur J Endocrinol 1994;131:33–40. ISSN 0804–4643 Insulin-like growth factor I (IGF-I) circulates bound to specific binding proteins (BPs) that modulate its effects at target cells. Hypoglycemia alters the serum levels of insulin-dependent IGFBPs and thus modifies the IGF-I action. We administered recombinant IGF-I (40 μg/kg body wt, from Kabi Pharmacia) in a morning dose (08.00 h) for seven consecutive days to six patients (21–47 years) with panhypopituitarism. This dose did not lead to hypoglycemia. Repeated blood sampling was performed on days 1 and 7, otherwise morning samples were drawn. The mean serum total IGF-I was maximal 3–4 h after the injection. A higher peak and basal value (p < 0.05) was observed on day 7 when compared to that observed on day 1. The concentrations were 237 vs 190 μg/l and 43 vs 22 μg/l. The mean free IGF-I increased concomitantly to 17 and 20 μg/l after 2–3 h on days 1 and 7. After 4 h, IGF-II was decreased (p <0.05) from 340 to 291 μg/l on day 1 and from 341 to 252 μg/l on day 7. The IGF-I area under the curve on days 1 and 7 was correlated to the IGFBP-3 levels. Only the patient with the highest IGFBP-3 level obtained IGF-I levels above 100 μg/l for 24 h. In spite of unchanged glucose levels, there was a modest suppression of insulin levels (p < 0.05) between 0 and 4 h from 102 to 78 pmol/l on day 1 and from 90 to 60 pmol/l on day 7 when the subjects were fasting. A small decline of mean potassium concentrations was found 2–6 h after the injection on day 1. During a week with daily injections, the morning serum IGF-I increased slightly in comparison to basal levels but no significant change in morning values of IGFBP-1, -2, -3, glucose and insulin were observed. Serum urea, creatinine, cholesterol and free fatty acid decreased significantly, indicating metabolic effects of IGF-I. Thus IGF-I has metabolic effects in doses not leading to hypoglycemia. To achieve a normal diurnal IGF-I level, recombinant IGF-I should be administered two or three times per 24 h in subjects with subnormal IGFBP-3 levels. Marja Thorén, Department of Endocrinology and Diabetology, Karolinska Hospital, S-171 76 Stockholm, Sweden

scholarly journals SURYANAMASKAR : A LIFESTYLE MODIFICATION IN PREDIABETES

2021 ◽  
Vol 9 (01) ◽  
Author(s):  
Rashmi Moogi ◽  
Vinayak Galatage
Keyword(s):  
Metabolic Disease ◽  
Insulin Resistance ◽  
Lifestyle Modification ◽  
Term Effect ◽  
Scientific Review ◽  
The Past ◽  
Long Term Effect ◽  
History Of ◽  
Positive Effect

ABSTRACT: With rapid economic development and increasing westernization of lifestyle in the past few decades, prevalence of the life style disorders has reached alarming proportions among Indians in the recent years. In 2011, in India there were 62.4 million people with diabetes and 77.2 million people with prediabetes. Prediabetes should be viewed in the natural history of disordered glucose metabolism rather than as a distinctive clinical entity. Prediabetes is the precursor stage to DM .It is metabolic disease associated with insulin resistance. As it is metabolic disorder it needs to be corrected with lifestyle modification. Suryanamaskar is such lifestyle modification therapy. Suryanamaskar exerts positive and long-term effect on prediabetes it delays and prevents the disease progress. However, this effects of Suryanamaskar therapy in prediabetes   management remain unclear and a matter of debate and research. This article offers a scientific review on positive effect of Suryanamaskar in prediabetes.      KEY WORDS: suryanamaskar, prediabetes , lifestyle disorders.   

Greater potency of IGF-I than IGF-I/BP-3 complex in catabolic parenterally fed rats

2000 ◽  
Vol 278 (2) ◽  
pp. E252-E262 ◽  
Author(s):  
K. R. Kritsch ◽  
D. J. Huss ◽  
D. M. Ney
Keyword(s):  
Serum Insulin ◽  
Male Rats ◽  
Total Serum ◽  
Pharmacokinetic Analysis ◽  
Mrna Levels ◽  
Recombinant Human Insulin ◽  
Glucose Levels ◽  
Factor I ◽  
Igf I ◽  
Igfbp 3

We compared the anabolic effects of recombinant human insulin-like growth factor I (rhIGF-I, 2.5 mg/kg) and equimolar amounts of rhIGF-I prebound to rhIGF binding protein-3 (rhIGF-I/BP-3) coinfused continuously with total parenteral nutrition (TPN) solution in dexamethasone (Dex, 70 μg/day ip)-treated male rats for 6 days. The four TPN groups included control, Dex, Dex + IGF-I, and Dex+IGF-I/BP-3. Pharmacokinetic analysis indicated reduced clearance of IGF-I when infused as IGF-I/BP-3 compared with free IGF-I (0.91 ± 0.09 vs. 2.01 ± 0.19 ml serum/min, P < 0.001) and this was associated with significantly greater serum IGF-I concentrations in the Dex+IGF-I/BP-3 group. Despite greater total serum IGF-I levels, infusion of free IGF-I produced greater anabolic responses than IGF-I/BP-3 based on body weight, nitrogen balance, and jejunal cellularity. Treatment with free IGF-I, but not IGF-I/BP-3, significantly reduced serum insulin and glucose levels that were elevated due to Dex. There were no significant differences in liver IGF-I mRNA levels between groups. Serum IGFBP-3 levels were elevated with infusion of IGF-I/BP-3 compared with IGF-I. These results indicate greater anabolic potency of IGF-I compared with IGF-I/BP-3 when administered by continuous parenteral infusion with TPN solution in catabolic rats.

Sign in / Sign up

Export Citation Format

Share Document